Organon & Co. (OGN)
Organon & Co. - Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use ofNEXPLANON® (etonogestrel implant) 68 mg Radiopaque
Organon & Co. - Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use ofNEXPLANON® (etonogestrel implant) 68 mg Radiopaque
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak signals • Minimal impact expected **Sentiment:** Neutral (50%) **Content type:** General